ArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ArQule (ARQL) PT Raised to $8 at Oppenheimer
March 8, 2019 9:11 AM ESTOppenheimer analyst Hartaj Singh raised the price target on ArQule (NASDAQ: ARQL) to $8.00 (from $7.00) while maintaining a Outperform rating following the company's 4Q report. Results were in line with Oppenheimer's estimates and expectations. Singh has updated the model for 2019, with estimates in line with... More
Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531
March 7, 2019 1:44 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $7 price target on ArQule (NASDAQ: ARQL) after a partial response was observed in ibrutinib refractory C481S mutant patient with ARQ-531.
"ArQule reported that the first patient treated in the current 7th... More
ArQule (ARQL) Surges 40% Following Results, Update
March 7, 2019 9:27 AM ESTArQule (NASDAQ: ARQL) is gaining 40% in pre-open trade following results and update.
... More